The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
